Systemic Lupus Erythematosus Treatment Market Research Report - Global Forecast till 2027

Systemic Lupus Erythematosus Treatment Market Size, Growth and Insights By Treatment (Corticosteroids, Nonsteroidal anti-inflammatory drugs, Antimalarials, Immunosuppressive agents and immune modulators), By Route of Administration (Oral, Intravenous, Subcutaneous) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Forecast to 2027

ID: MRFR/HC/7028-HCR | February, 2021 | Region : Global

Systemic Lupus Erythematosus Treatment Market Synopsis


Systemic Lupus Erythematosus Treatment Market is expected to cross USD 1.5 Billion by 2025 at a CAGR of 6%. Systemic lupus erythematosus is a disease that causes inflammation in connective tissues, like the lining of blood vessels and cartilage. Systemic lupus erythematosus medication includes nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and corticosteroids amongst others. Early Systemic lupus erythematosus diagnosis and treatment can help to reduce the adverse effects of SLE and improve the chances of having a better life. SLE treatment currently includes administering drugs from four categories, namely corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and Immunosuppressive agents and immune modulators.


Systemic Lupus Erythematosus Treatment Market Influencer


Research and development for the launch of drugs, by key players, for the treatment of systemic lupus erythematosus.


Market Drivers



  • High prevalence & incidence of systemic lupus erythematosus: The worldwide prevalence of systemic lupus erythematosus in 2018 was estimated to be 150 per 100,000 individuals with an incidence of around 1 to 10 per 100,000 persons per year.



  • Product launches by key players



  • Strong product pipeline: As of the third quarter of the year 2019, there were around 170 ongoing clinical trials on systemic lupus erythematosus (SLE).



  • Increasing awareness regarding systemic lupus erythematosus


Market Restraints



  • Stringent regulatory policies

  • Side effects of medications


Systemic Lupus Erythematosus Treatment Market Segmentation


By Treatment



  • Corticosteroids: SLE treatment involves the use of corticosteroids, which inhibits the immune system from attacking the healthy cells of the body. Prednisone is the most frequently prescribed corticosteroid for the treatment of systemic lupus erythematosus.



  • Nonsteroidal anti-inflammatory drugs (NSAIDs): This class of drugs decreases pain, reduces fever, and decreases inflammation. In around 80% of the cases, systemic lupus erythematosus medication involves the use of Nonsteroidal anti-inflammatory drugs (NSAIDs).



  • Antimalarials: Although initially antimalarials were used to treat malaria, it was later found that these drugs help reduce joint and muscle pain, inflammation of the lining of the lungs and heart, fatigue, and other symptoms of lupus. New drug approvals are expected to drive the growth of this segment. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for its generic version of antimalarial Plaquenil.



  • Immunosuppressive agents and immune modulators: In specific cases, immunosuppressive agents can be used to suppress the overactive immune response. The increasing demand for drugs is expected to drive the growth of this segment. For instance, in 2018, sales of ballista (an immunosuppressant drug) increased by 24% in the US as compared to that in 2017.


By Route of Administration



  • Oral: This segment generally involves tablets and capsules for the treatment of systemic lupus erythematosus.



  • Intravenous: This category includes drugs administered via veins of the patient and has shown a faster effect as compared to drugs administered via oral route.



  • Subcutaneous: Drugs injected under the skin, generally using a needle and syringe, are included under this category.


By Distribution Channel



  • Hospital Pharmacies: Since patients admitted to hospitals prefer hospital pharmacies for purchasing prescribed drugs, and due to an increase in the number of hospitals, hospital pharmacies segment is expected to hold the largest share in the year 2018.



  • Retail Pharmacies: The segment is expected to hold the second-largest systemic lupus erythematosus treatment market share.



  • Online Pharmacies: It is expected to be the fastest-growing segment during the forecast period as increasing awareness regarding E-commerce has resulted in a growing trend for purchasing medicines online.


By Region



  • Americas: Holds the largest systemic lupus erythematosus treatment market share due to high healthcare expenditure and the presence of key market players.



  • Europe: The second-largest regional systemic lupus erythematosus treatment market due to increasing research and measures taken for SLE management.



  • Asia-Pacific: The fastest-growing regional systemic lupus erythematosus treatment market, due to increasing awareness regarding systemic lupus erythematosus treatment and increasing population affected by SLE.



  • Middle East & Africa: The smallest systemic lupus erythematosus treatment market due to limited healthcare infrastructure and lack of awareness regarding systemic lupus erythematosus treatment options.


Systemic Lupus Erythematosus Treatment Market Key Players



  • Sanofi (France)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Pfizer Inc. (US)

  • GlaxoSmithKline plc (UK)

  • AstraZeneca (UK)

  • Eli Lilly and Company (US)

  • Bristol-Myers Squibb Company (US)

  • Amgen Inc. (US)

  • Anthera (US)

  • Johnson & Johnson Services, Inc. (US)

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Systemic Lupus Erythematosus Treatment Market, by Treatment

6.1 Overview

6.2 Corticosteroids

6.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

6.4 Antimalarials

6.5 Immunosuppressive Agents and Immune Modulators

6.6 Others

Chapter 7. Global Systemic Lupus Erythematosus Treatment Market, by Route of Administration

7.1 Introduction

7.2 Oral

7.3 Intravenous

7.4 Subcutaneous

Chapter 8. Global Systemic Lupus Erythematosus Treatment Market, by Distribution Channel

8.1 Introduction

8.2 Hospital Pharmacies

8.3 Retail Pharmacies

8.4 Online Pharmacies

Chapter 9. Global Systemic Lupus Erythematosus Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

Chapter 10. Competitive Landscape

10.1 Overview

10.2 Competitive Analysis

10.3 Market Share Analysis

10.4 Major Growth Strategy in the Global Cough & Cold Treatment Market

10.5 Competitive Benchmarking

10.6 Leading Player in terms of Number of Developments in Global Cough & Cold Treatment Market

10.7 Key Developments & Growth Strategies

10.7.1 New Treatment Launch/Service Deployment

10.7.2 Merger & Acquisition

10.7.3 Joint Ventures

10.8 Major Players Financial Matrix & Market Ratio

10.8.1 Sales & Operating Income 2020

10.8.2 Major Players R&D Expenditure 2020

10.8.3 Major Players Capital Market Ratio

Chapter 11 Company Profiles

11.1 Sanofi

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Treatments Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2 F. Hoffmann-La Roche Ltd

11.2.1 Company Overview

11.2.2 Financial Overview

11.2.3 Treatments Offered

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.2.6 Key Strategies

11.3 Novartis AG

11.3.1 Company Overview

11.3.2 Financial Overview

11.3.3 Treatments Offered

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.3.6 Key Strategies

11.4 Pfizer Inc.

11.4.1 Company Overview

11.4.2 Financial Overview

11.4.3 Treatments Offered

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.4.5 Key Strategies

11.5 GlaxoSmithKline plc

11.5.1 Company Overview

11.5.2 Financial Overview

11.5.3 Treatments Offered

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.5.6 Key Strategies

11.6 AstraZeneca

11.6.1 Company Overview

11.6.2 Financial Overview

11.6.3 Treatments Offered

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.6.6 Key Strategies

11.7 Eli Lilly and Company

11.7.1 Company Overview

11.7.2 Financial Overview

11.7.3 Treatments Offered

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7.6 Key Strategies

11.8 Bristol-Myers Squibb Company

11.8.1 Company Overview

11.8.2 Financial Overview

11.8.3 Treatments Offered

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8.6 Key Strategies

11.9 Amgen Inc.

11.9.1 Company Overview

11.9.2 Financial Overview

11.9.3 Treatments Offered

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9.6 Key Strategies

11.10 Anthera

11.10.1 Company Overview

11.10.2 Financial Overview

11.10.3 Treatments Offered

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10.6 Key Strategies

11.11 Johnson & Johnson Services, Inc.

11.11.1 Company Overview

11.11.2 Financial Overview

11.11.3 Treatments Offered

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.11.5 Key Strategies

11.12 Others

11.12.1 Company Overview

11.12.2 Financial Overview

11.12.3 Treatments Offered

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.12.6 Key Strategies

Chapter 12. Appendix

12.1. References

12.2. Related Reports


LIST OF TABLES

Table 1 Global Systemic Lupus Erythematosus Treatment Synopsis, 2020-2027

Table 2 Global Systemic Lupus Erythematosus Treatment Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Systemic Lupus Erythematosus Treatment Market, by Region, 2020-2027 (USD Million)

Table 4 Global Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 6 Global Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 8 Global Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)

Table 9 Americas: Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 11 Americas: Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 13 Americas: Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)

Table 14 Americas: Systemic Lupus Erythematosus Treatment Market, by Region, 2020-2027 (USD Million)

Table 15 North America: Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 17 North America: Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 19 North America: Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)

Table 20 Latin America: Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 22 Latin America: Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 24 Latin America: Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)

Table 25 Europe: Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 27 Europe: Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 29 Europe: Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)

Table 30 Europe: Systemic Lupus Erythematosus Treatment Market, by Region, 2020-2027 (USD Million)

Table 31 Western Europe: Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 33 Western Europe: Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 35 Western Europe: Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)

Table 36 Eastern Europe: Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 38 Eastern Europe: Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 40 Eastern Europe: Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)

Table 41 Asia-Pacific: Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 43 Asia-Pacific: Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 45 Asia-Pacific: Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)

Table 46 Middle East & Africa: Systemic Lupus Erythematosus Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 48 Middle East & Africa: Systemic Lupus Erythematosus Treatment Market, by Route of Administration, 2020-2027 (USD Million)

Table 50 Middle East & Africa: Systemic Lupus Erythematosus Treatment Market, by Distribution Channel, 2020-2027 (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation of the Global Systemic Lupus Erythematosus Treatment Market

Figure 3 Market Dynamics for the Global Systemic Lupus Erythematosus Treatment Market

Figure 4 Global Systemic Lupus Erythematosus Treatment Market Share, by Treatment, 2020

Figure 5 Global Systemic Lupus Erythematosus Treatment Market Share, by Route of Administration, 2020

Figure 6 Global Systemic Lupus Erythematosus Treatment Market Share, by Distribution Channel, 2020

Figure 7 Global Systemic Lupus Erythematosus Treatment Market Share, by Region, 2020

Figure 8 Americas: Systemic Lupus Erythematosus Treatment Market Share, by Region, 2020

Figure 9 North America: Systemic Lupus Erythematosus Treatment Market Share, by Country, 2020

Figure 10 Latin America: Systemic Lupus Erythematosus Treatment Market Share, by Country, 2020

Figure 11 Europe: Systemic Lupus Erythematosus Treatment Market Share, by Country, 2020

Figure 12 Asia-Pacific: Systemic Lupus Erythematosus Treatment Market Share, by Country, 2020

Figure 13 Middle East & Africa: Systemic Lupus Erythematosus Treatment Market Share, by Country, 2020

Figure 14 Global Systemic Lupus Erythematosus Treatment Market: Company Share Analysis, 2020 (%)

Figure 15 Sanofi: Key Financials

Figure 16 Sanofi: Segmental Revenue

Figure 17 Sanofi: Regional Revenue

Figure 18 F. Hoffmann-La Roche Ltd: Key Financials

Figure 19 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 20 F. Hoffmann-La Roche Ltd: Regional Revenue

Figure 21 Novartis AG: Key Financials

Figure 22 Novartis AG: Segmental Revenue

Figure 23 Novartis AG: Regional Revenue

Figure 24 Pfizer Inc.: Key Financials

Figure 25 Pfizer Inc.: Segmental Revenue

Figure 26 Pfizer Inc.: Regional Revenue

Figure 27 GlaxoSmithKline plc: Key Financials

Figure 28 GlaxoSmithKline plc: Regional Revenue

Figure 29 GlaxoSmithKline plc: Key Financials

Figure 30 AstraZeneca: Segmental Revenue

Figure 31 AstraZeneca: Regional Revenue

Figure 32 AstraZeneca: Key Financials

Figure 33 Eli Lilly and Company: Segmental Revenue

Figure 34 Eli Lilly and Company: Regional Revenue

Figure 35 Eli Lilly and Company: Key Financials

Figure 36 BRISTOL-MYERS SQUIBB COMPANY: Segmental Revenue

Figure 37 BRISTOL-MYERS SQUIBB COMPANY: Regional Revenue

Figure 38 BRISTOL-MYERS SQUIBB COMPANY: Key Financials

Figure 39 Amgen Inc.: Segmental Revenue

Figure 40 Amgen Inc.: Regional Revenue

Figure 41 Amgen Inc.: Key Financials

Figure 42 Anthera: Segmental Revenue

Figure 43 Anthera: Regional Revenue

Figure 44 Anthera: Key Financials

Figure 45 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 46 Johnson & Johnson Services, Inc.: Regional Revenue

Figure 47 Johnson & Johnson Services, Inc.: Key Financials




This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Systemic Lupus Erythematosus Treatment Market